Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098663092> ?p ?o ?g. }
- W2098663092 endingPage "163" @default.
- W2098663092 startingPage "163" @default.
- W2098663092 abstract "The aim of this experiment was to evaluate the effects of cycloxigenase inhibitor drugs, i.e. flunixin meglumine (FM) and parecoxib (P), on the development of bovine embryos cultured in vitro until the blastocyst and hatched blastocyst stages. Immature oocytes were aspirated from slaughterhouse ovaries and morphologically selected for IVM (Monteiro FM et al. 2007 Anim. Reprod. 4, 51–58). Twenty hours after maturation (39°C and 5% CO2 in air), matured oocytes were transferred to fertilization media, inseminated with frozen–thawed semen, and incubated for 10 to 12 h. Presumptive zygotes (PZ) were then transferred to TCM 199 HEPES medium, vortexed to remove cumulus cells and finally to drops of IVC media (SOFaaci plus 5% BFS [Gibco] with 13 mm sodium pyruvate). Each drop of IVC medium had appropriate concentrations of FM (0.14/n = 123; 1.4/n = 122; 14/n = 117; 140/n = 44 or 1400 μg mL–1/n = 44 PZ) or P (0.09/n = 134; 0.9/n = 109; 9/n = 118; 90/n = 113 or 900 μg mL–1/n = 45 PZ), besides extra drops as control groups (CFM; n = 124 and CP; n = 149 PZ). Based on published data from bovine (FM) and human (P) administered concentrations, it was calculated the blood concentration to a bovine weighing 450 kg (FM = 14 and P = 9 μg mL–1). Both drugs were used from available commercial preparations, and in a pilot test, there were no deleterious effects of the solvent itself on the blastocyst and hatched blastocyst rates. During culture, petri dishes containing PZ/embryos were kept into plastic bags, under controlled atmosphere of 5% O2, 5% CO2 and 90% N2 at 39°C. There were 11 replicates for each treatment. In all drops (both drug concentrations and control group) the blastocyst and hatched blastocyst rates (BR and HBR, respectively) were evaluated at 144 and 192 h after fertilization, respectively. Statistical analysis was performed with ANOVA on ranks (Dunn’s test a posteriori and significance being considered when P < 0.05; BioEstat version 5.0). According to the results, FM (1400 and 140 μg mL–1) and P (900 μg mL–1) concentrations were toxic enough for a complete inhibition of in vitro bovine embryo development. There were no significant differences among the other drug concentrations and their respective control group, on the BR (27.7 ± 3.9; 29.6 ± 3.4 and 29.8% ± 4.8) and HBR (13.5 ± 4.4; 15.6 ± 3.8 and 22.1% ± 5.1), respectively to 0.14; 1.4 and 14 μg mL–1 for FM; on BR (26.0 ± 2.6; 18.2 ± 4.6; 25.8 ± 5.9 and 23.2% ± 4.8) and HBR (14.1 ± 3.3; 10.2 ± 3.3; 16.8 ± 3.8 and 12.0% ± 3.4), respectively to 0.09; 0.9; 9 and 90 μg mL–1 for P; and on BR (35.3 ± 5.2 and 36.5% ± 3.4) and HBR (26.6 ± 4.5 and 19.8% ± 3.6), respectively for CFM and CP. The results suggest that, during in vitro bovine embryo culture, there was no significant toxicity of either drug, with exception of the complete lethal concentrations of 140 and 1400 μg mL–1 (flunixin meglumine) and 900 μg mL–1 (parecoxib) on blastocyst production. Supported by FAPESP – Brazil (MFGN 06/06491-2 and 07/07705-9; EMR 07/04284-2; RAS; CFS and RALS) and CAPES – Brazil." @default.
- W2098663092 created "2016-06-24" @default.
- W2098663092 creator A5003988821 @default.
- W2098663092 creator A5007237842 @default.
- W2098663092 creator A5007710527 @default.
- W2098663092 creator A5009923543 @default.
- W2098663092 creator A5013050942 @default.
- W2098663092 creator A5028108743 @default.
- W2098663092 creator A5030585073 @default.
- W2098663092 creator A5050216471 @default.
- W2098663092 creator A5071372073 @default.
- W2098663092 date "2009-01-01" @default.
- W2098663092 modified "2023-10-09" @default.
- W2098663092 title "127 LETHAL EFFECT OF HIGH CONCENTRATIONS OF PARECOXIB AND FLUNIXIN MEGLUMINE ON THE IN VITRO CULTURE OF BOVINE EMBRYOS" @default.
- W2098663092 cites W1494051865 @default.
- W2098663092 cites W1972078581 @default.
- W2098663092 cites W1988600076 @default.
- W2098663092 cites W1990587304 @default.
- W2098663092 cites W2016140930 @default.
- W2098663092 cites W2017861034 @default.
- W2098663092 cites W2019753523 @default.
- W2098663092 cites W2029239026 @default.
- W2098663092 cites W2047332147 @default.
- W2098663092 cites W2085687511 @default.
- W2098663092 cites W2094681394 @default.
- W2098663092 cites W2101715380 @default.
- W2098663092 cites W2123030226 @default.
- W2098663092 cites W2124680574 @default.
- W2098663092 cites W2152310059 @default.
- W2098663092 cites W2158618482 @default.
- W2098663092 cites W2168717627 @default.
- W2098663092 cites W2169632325 @default.
- W2098663092 cites W2283279647 @default.
- W2098663092 cites W2324916535 @default.
- W2098663092 cites W3092678410 @default.
- W2098663092 doi "https://doi.org/10.1071/rdv21n1ab127" @default.
- W2098663092 hasPublicationYear "2009" @default.
- W2098663092 type Work @default.
- W2098663092 sameAs 2098663092 @default.
- W2098663092 citedByCount "1" @default.
- W2098663092 countsByYear W20986630922014 @default.
- W2098663092 crossrefType "journal-article" @default.
- W2098663092 hasAuthorship W2098663092A5003988821 @default.
- W2098663092 hasAuthorship W2098663092A5007237842 @default.
- W2098663092 hasAuthorship W2098663092A5007710527 @default.
- W2098663092 hasAuthorship W2098663092A5009923543 @default.
- W2098663092 hasAuthorship W2098663092A5013050942 @default.
- W2098663092 hasAuthorship W2098663092A5028108743 @default.
- W2098663092 hasAuthorship W2098663092A5030585073 @default.
- W2098663092 hasAuthorship W2098663092A5050216471 @default.
- W2098663092 hasAuthorship W2098663092A5071372073 @default.
- W2098663092 hasBestOaLocation W20986630922 @default.
- W2098663092 hasConcept C105702510 @default.
- W2098663092 hasConcept C16685009 @default.
- W2098663092 hasConcept C185592680 @default.
- W2098663092 hasConcept C196843134 @default.
- W2098663092 hasConcept C202751555 @default.
- W2098663092 hasConcept C2776690073 @default.
- W2098663092 hasConcept C2777324261 @default.
- W2098663092 hasConcept C2778177303 @default.
- W2098663092 hasConcept C55493867 @default.
- W2098663092 hasConcept C71924100 @default.
- W2098663092 hasConcept C86803240 @default.
- W2098663092 hasConcept C87073359 @default.
- W2098663092 hasConcept C88972607 @default.
- W2098663092 hasConcept C95444343 @default.
- W2098663092 hasConceptScore W2098663092C105702510 @default.
- W2098663092 hasConceptScore W2098663092C16685009 @default.
- W2098663092 hasConceptScore W2098663092C185592680 @default.
- W2098663092 hasConceptScore W2098663092C196843134 @default.
- W2098663092 hasConceptScore W2098663092C202751555 @default.
- W2098663092 hasConceptScore W2098663092C2776690073 @default.
- W2098663092 hasConceptScore W2098663092C2777324261 @default.
- W2098663092 hasConceptScore W2098663092C2778177303 @default.
- W2098663092 hasConceptScore W2098663092C55493867 @default.
- W2098663092 hasConceptScore W2098663092C71924100 @default.
- W2098663092 hasConceptScore W2098663092C86803240 @default.
- W2098663092 hasConceptScore W2098663092C87073359 @default.
- W2098663092 hasConceptScore W2098663092C88972607 @default.
- W2098663092 hasConceptScore W2098663092C95444343 @default.
- W2098663092 hasIssue "1" @default.
- W2098663092 hasLocation W20986630921 @default.
- W2098663092 hasLocation W20986630922 @default.
- W2098663092 hasLocation W20986630923 @default.
- W2098663092 hasOpenAccess W2098663092 @default.
- W2098663092 hasPrimaryLocation W20986630921 @default.
- W2098663092 hasRelatedWork W1972453963 @default.
- W2098663092 hasRelatedWork W2014598994 @default.
- W2098663092 hasRelatedWork W2033082795 @default.
- W2098663092 hasRelatedWork W2046745697 @default.
- W2098663092 hasRelatedWork W2166971475 @default.
- W2098663092 hasRelatedWork W2346409371 @default.
- W2098663092 hasRelatedWork W2349296746 @default.
- W2098663092 hasRelatedWork W2389182588 @default.
- W2098663092 hasRelatedWork W2911155877 @default.
- W2098663092 hasRelatedWork W4223472953 @default.
- W2098663092 hasVolume "21" @default.
- W2098663092 isParatext "false" @default.